A Philadelphia jury has slammed the makers of Xarelto with an almost $28 million verdict after finding the companies failed to adequately warn about the Xarelto bleeding risks associated with the blood thinner.

On Tuesday, the jury ordered Bayer AG and Johnson & Johnson, which jointly developed Xarelto, to pay $1.8 million in compensatory damages and a whopping $26 million in punitive damages.

This verdict marks the drugmakers’ first loss in a Xarelto bleeding lawsuit. Three bellwether cases from the sprawling Xarelto multidistrict litigation resulted in juries siding with the drugmakers. These Xarelto lawsuit trials were held in federal courts in Louisiana and Mississippi.

Plaintiff Lynn H. filed the Xarelto lawsuit in 2015. She claims she suffered a serious gastrointestinal bleed while she was using Xarelto. In her Xarelto trial, she argued that Bayer J&J subsidiary Janssen Pharmaceuticals failed to include information on the drug’s warning label indicating that the rate of Xarelto bleeding events observed during a clinical trial was higher than those observed in patients in Europe.

Lynn suggested that the European Xarelto trials may have been rigged. She alleges that a Xarelto trial that took place in Europe included a high number of patients who were more likely to suffer adverse effects from warfarin, a competing drug that requires a higher level of monitoring than other blood thinners available on the market.

According to Lynn’s Xarelto bleeding lawsuit, the European trial results were skewed to make the risk of Xarelto bleeding seem less severe. She says that the results of the European Xarelto trial made the Xarelto bleeding risks seem on par with those of warfarin, when Xarelto actually poses a much greater risk of a severe bleeding event.

Lynn claims she began taking Xarelto in 2013 for the prevention of stroke and blood clots associated with atrial fibrillation. She suffered a severe gastrointestinal bleed in June 2014, which allegedly required four blood transfusions. She has reportedly switched to a different blood thinner and has not had further problems.

“Xarelto is the worst in class of the new blood thinners,” Michael Weinkowitz, an attorney who represents Lynn, said in a statement. “The serious health complications suffered by thousands of patients could have been avoided if physicians were properly instructed about the risks.”

Lynn’s Xarelto lawsuit was the first to go to trial out of roughly 1,400 cases pending in Philadelphia state court, which has a reputation for having plaintiff-friendly juries, according to Bloomberg.com.

More than 18,000 Xarelto lawsuits are currently pending in multidistrict litigation, which has been consolidated in the U.S. District Court for the Eastern District of Louisiana.

Bayer and J&J have said that they plan to appeal the Philadelphia jury’s finding that they failed to properly warn about Xarelto bleeding risks.

Lynn H. is represented by Gary Douglas of Douglas & London PC; Michael Weinkowitz and Frederick Longer of Levin Sedran & Berman; Ned McWilliams of Levin Papantonio; and Laura Feldman of Feldman & Pinto.

The Xarelto Bleeding Lawsuit is Lynn H. v. Janssen Pharmaceuticals, et al., Case No. 160503416, in the Court of Common Pleas of Philadelphia County, Pennsylvania.